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Recommendations for the perinatal treatment of women colonized with Streptococcus agalactiae include
vancomycin prophylaxis for those with severe penicillin allergies and antibiotic-resistant organisms. Because
of potential postpartum infections due to vancomycin-resistant enterococci (VRE) and the possible spread of
vancomycin resistance, the prevalence of VRE in prenatal screening cultures was determined.
Enterococcus spp. are a component of the human intestinal
flora and may be found naturally in the birth canals of women.
These organisms are also a common cause of hospital-acquired
urinary tract, wound, and bloodstream infections. Although
Enterococcus is rarely reported to cause perinatally acquired
neonatal infections, it is commonly isolated from women with
postcesarean endometritis and wound infections (3, 18, 24, 29).
Streptococcus agalactiae can also colonize the vaginas and/or
recta of women and is a well-described neonatal pathogen that
is transmitted perinatally. Vertical transmission of S. agalactiae
is associated with increased morbidity and mortality in neo-
nates due to pneumonia, sepsis, and meningitis (11, 17). An-
timicrobial resistance is an increasing problem for both of
these organisms. Vancomycin-resistant enterococci (VRE) are
more refractory to treatment than their sensitive counterparts,
and S. agalactiae is becoming increasingly resistant to erythro-
mycin and clindamycin (1, 14–16, 23).
In 2002, the Centers for Disease Control and Prevention
recommended that all pregnant women be screened for the
presence of S. agalactiae (group B Streptococcus) and pub-
lished guidelines for the treatment of colonized pregnant
women (5). Penicillin is the drug of choice for the prophylactic
treatment of S. agalactiae. For severely penicillin-allergic
mothers, the alternative treatment is either erythromycin or
clindamycin. However, antibiotic resistance among S. agalac-
tiae isolates is increasing. At the University of North Carolina
Hospitals, 31% of S. agalactiae isolates were found to be re-
sistant to erythromycin and two-thirds of these isolates were
also resistant to clindamycin (M. B. Miller, M. C. Jones, E.
Rogers, V. Lang, and P. H. Gilligan, Abstr. 103rd Gen. Meet.
Am. Soc. Microbiol., abstr. C-124, 2003). Further, in some
cases, in vitro susceptibility data may not be available for pre-
natal isolates. In these instances, vancomycin has been recom-
mended for prophylaxis of perinatal S. agalactiae infection.
The use of vancomycin in penicillin-allergic women may
precipitate an increase in the presence of VRE in this popu-
lation, which raises at least two concerns. First, if postpartum
infections develop in either the mother or the neonate, empir-
ical therapy with vancomycin will not be effective. Second,
since vancomycin resistance can be transferred between bac-
teria, the presence of VRE might promote an increase in
vancomycin resistance in other vaginal or rectal gram-positive
organisms (6, 12, 19). Therefore, to assess the potential for
VRE-associated postpartum infections and the possible bacte-
rial transfer of vancomycin resistance in this patient popula-
tion, the prevalence of VRE in routine prenatal screening
cultures was determined.
(A preliminary report of this work has been presented pre-
viously [S. L. Allen, M. E. Mangum, M. B. Miller, A. Doutova,
and P. H. Gilligan, Abstr. 103rd Gen. Meet. Am. Soc. Micro-
biol., abstr. C-413, 2003].)
Specimens (n  447) received for prenatal S. agalactiae
screening were inoculated into LIM enrichment broth and
subsequently plated on sheep blood agar and Thayer-Martin
(improved) medium (Remel, Lenexa, Kans.). Cultured sources
included vaginal and rectal (197 specimens), vaginal (185 spec-
imens), cervical (54 specimens), endocervical (5 specimens),
rectal (5 specimens), and unspecified (1 specimen) sites. How-
ever, it should be noted that a chart review revealed that many
of the swabs labeled as vaginal were, in fact, vaginal and rectal
swabs. Growth on Thayer-Martin (improved) medium (3 g of
vancomycin/ml) was used as a first screen for the presence of
Enterococcus with reduced susceptibility to vancomycin. Colo-
nies consistent with Enterococcus were identified with Gram
stain, catalase, bile esculin, and 6.5% NaCl media and by the
pyrrolidonyl aminopeptidase test. Vancomycin MICs were de-
termined by the Etest (Remel). All other susceptibility results
were determined by disk diffusion (Becton Dickinson, Cock-
eysville, Md.) by using NCCLS interpretation guidelines. Iso-
lates exhibiting resistance to vancomycin were further identi-
fied to species level on the basis of arabinose utilization,
arginine decarboxylase activity, methyl--D-glucopyranoside
acidification, motility, and pigmentation (4, 7, 9, 22, 30). Mul-
tiplex PCR for the van genes was performed with Enterococcus
isolates as previously described (8, 10, 20). Genomic DNA for
pulsed-field gel electrophoresis (PFGE) was prepared, di-
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gested with SmaI or NotI, and then subjected to PFGE
(CHEF-DR III system; Bio-Rad, Hercules, Calif.) as described
previously (2, 8, 21). The resulting banding patterns were in-
terpreted according to published recommendations (26).
Sixty-eight percent of the prenatal screening cultures grew
Enterococcus (305 isolates). For 5.6% of the Enterococcus iso-
lates, intermediate vancomycin MICs were 4 to 8 g/ml (17
isolates). The 17 Enterococcus species identified included E.
gallinarum (14 isolates) and E. casseliflavus (3 isolates), which
are known to have low-level intrinsic resistance to vancomycin
due to nontransferable van genes (vanC-1 and vanC-2, respec-
tively). PCR was performed to confirm the van resistance de-
terminants of these isolates. A multiplex PCR with vanA and
vanB primers did not produce any PCR products for the 17
isolates in question, whereas the results of vanC-1 and vanC-2
multiplex PCR confirmed that all isolates identified as E. galli-
narum harbored vanC-1 but that the isolates identified as E.
casseliflavus contained vanC-2.
Susceptibilities to seven commonly tested drugs were deter-
mined for the 17 Enterococcus isolates that were recovered
from prenatal screening cultures. All of the isolates were sen-
sitive to ampicillin, high-concentration gentamicin, chloram-
phenicol, and linezolid. Two isolates were resistant to high-
concentration streptomycin, and resistance to tetracycline was
observed for four isolates. Interestingly, all of the isolates that
exhibited reduced susceptibility to vancomycin also showed
reduced susceptibility to quinupristin-dalfopristin (10 isolates
were intermediate, and 7 were resistant). While intrinsic resis-
tance to streptogramins is known for Enterococcus faecalis,
previous reports have not indicated increased levels of resis-
tance among E. casseliflavus and E. gallinarum isolates (13, 25).
In addition, only two of the 17 enterococci isolated from pre-
natal cultures appeared to be genetically related as determined
by PFGE.
The data presented suggest that there is little resistance
among Enterococcus strains recovered from screened pregnant
women. Of the prenatal cultures, 3.8% contained Enterococcus
isolates with intermediate resistance to vancomycin. Previous
reports have demonstrated rectal colonization rates of vanC-
containing enterococci ranging from 5 to 12% in various pop-
ulations (27, 28). The colonization rate observed for prenatal
cultures is lower likely due to the screening of specimens that
did not include a rectal component. However, there are no
published data regarding the prevalence of these organisms in
nonrectal sites. Although this study suggests a 2.7% vaginal
colonization rate for vanC-containing enterococci, this rate
may be a misrepresentation due to clerical errors with regard
to site identification.
Since none of the Enterococcus strains isolated contained
vanA or vanB, there does not presently seem to be a threat of
vancomycin resistance genes being transferred to other gram-
positive species found in the vaginal and rectal sites of the
women involved in this study. However, as the number of S.
agalactiae isolates that are resistant to erythromycin and clin-
damycin increases, the use of vancomycin to treat penicillin-
allergic pregnant women who harbor S. agalactiae will also
increase. Thus, the incidence of VRE in this patient population
may also increase, leading to the failure of empirical treatment
with vancomycin for postpartum infections and the possible
transfer of vancomycin resistance genes to other gram-positive
species.
This study was approved by the Institutional Review Board of the
University of North Carolina School of Medicine.
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